Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc (MDGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,915,730
  • Shares Outstanding, K 21,810
  • Annual Sales, $ 0 K
  • Annual Income, $ -373,630 K
  • EBIT $ -548 M
  • EBITDA $ -545 M
  • 60-Month Beta -0.46
  • Price/Sales 88.87
  • Price/Cash Flow N/A
  • Price/Book 8.82

Options Overview Details

View History
  • Implied Volatility 56.56% ( -0.29%)
  • Historical Volatility 89.17%
  • IV Percentile 38%
  • IV Rank 13.12%
  • IV High 156.35% on 02/23/24
  • IV Low 41.48% on 08/19/24
  • Put/Call Vol Ratio 0.17
  • Today's Volume 608
  • Volume Avg (30-Day) 1,529
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 31,086
  • Open Int (30-Day) 27,492

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -4.65
  • Number of Estimates 9
  • High Estimate -3.86
  • Low Estimate -6.22
  • Prior Year -5.68
  • Growth Rate Est. (year over year) +18.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
200.63 +64.10%
on 10/23/24
368.29 -10.60%
on 11/07/24
+120.35 (+57.61%)
since 10/21/24
3-Month
200.63 +64.10%
on 10/23/24
368.29 -10.60%
on 11/07/24
+73.07 (+28.52%)
since 08/21/24
52-Week
168.25 +95.69%
on 02/09/24
368.29 -10.60%
on 11/07/24
+140.80 (+74.72%)
since 11/21/23

Most Recent Stories

More News
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

For Immediate ReleaseChicago, IL – November 11, 2024 – Today, Zacks Equity Research like Madrigal Pharmaceuticals MDGL, Corcept Therapeutics CORT, Catalyst Pharmaceuticals CPRX, Larimar Therapeutics...

CORT : 55.92 (-0.30%)
TBPH : 9.61 (-3.61%)
MDGL : 329.24 (+3.83%)
LRMR : 6.13 (+0.82%)
CPRX : 21.12 (-0.14%)
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More

There's a bright future ahead for this company.

MDGL : 329.24 (+3.83%)
5 Small Drug Stocks to Buy as Trump Gets Re-Elected

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic Inflation Reduction Act (“IRA”). With Donald Trump’s reelection, the biotech...

CORT : 55.92 (-0.30%)
TBPH : 9.61 (-3.61%)
MDGL : 329.24 (+3.83%)
LRMR : 6.13 (+0.82%)
CPRX : 21.12 (-0.14%)
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

MDGL : 329.24 (+3.83%)
Madrigal: Q3 Earnings Snapshot

Madrigal: Q3 Earnings Snapshot

MDGL : 329.24 (+3.83%)
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

MDGL : 329.24 (+3.83%)
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

MDGL : 329.24 (+3.83%)
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

MDGL : 329.24 (+3.83%)
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

MDGL : 329.24 (+3.83%)
SGMT Stock Up 12.6% on FDA Fast Track for Liver Disease Drug

Sagimet Biosciences’ SGMT stock rose 12.6% on Tuesday after it announced that the FDA has granted breakthrough therapy designation (“BTD”) to its lead pipeline candidate, denifanstat, for treating...

VKTX : 51.63 (+0.19%)
MDGL : 329.24 (+3.83%)
AKRO : 31.20 (+1.84%)
SGMT : 4.50 (-0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia...

See More

Key Turning Points

3rd Resistance Point 349.18
2nd Resistance Point 339.55
1st Resistance Point 334.40
Last Price 329.24
1st Support Level 319.62
2nd Support Level 309.99
3rd Support Level 304.84

See More

52-Week High 368.29
Last Price 329.24
Fibonacci 61.8% 291.87
Fibonacci 50% 268.27
Fibonacci 38.2% 244.66
52-Week Low 168.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar